Evidence map›Paper›PMID 38812930›Full record

ArticleFrontiers in nutrition2024

Lipid-lowering, antihypertensive, and antithrombotic effects of nattokinase combined with red yeast rice in patients with stable coronary artery disease: a randomized, double-blinded, placebo-controlled trial.

Man Liu, Ziyi Xu, Zongling Wang, Di Wang, Mingzhe Yang, Hui Li, Wei Zhang, Ruikun He, Huimin Cheng, Peiyu Guo and 2 more

Abstract read
In one paragraph

Article in Frontiers in nutrition, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Man Liu *The Institute of Human Nutrition, College of Public Health, Qingdao University, Qingdao, China.
Ziyi Xu *BYHEALTH Institute of Nutrition & Health, BYHEALTH Co. Ltd., Guangzhou, China.
Zongling WangQingdao Fuwai Cardiovascular Disease Hospital, Qingdao, China.
Di WangBYHEALTH Institute of Nutrition & Health, BYHEALTH Co. Ltd., Guangzhou, China.
Mingzhe YangBYHEALTH Institute of Nutrition & Health, BYHEALTH Co. Ltd., Guangzhou, China.
Hui LiSongshan Hospital, Medical College of Qingdao University, Qingdao, China.
Wei ZhangSongshan Hospital, Medical College of Qingdao University, Qingdao, China.
Ruikun HeBYHEALTH Institute of Nutrition & Health, BYHEALTH Co. Ltd., Guangzhou, China.
Huimin ChengThe Institute of Human Nutrition, College of Public Health, Qingdao University, Qingdao, China.
Peiyu GuoThe Institute of Human Nutrition, College of Public Health, Qingdao University, Qingdao, China.
Zhongxia LiBYHEALTH Institute of Nutrition & Health, BYHEALTH Co. Ltd., Guangzhou, China.
Hui LiangThe Institute of Human Nutrition, College of Public Health, Qingdao University, Qingdao, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nattokinase (NK) and red yeast rice (RYR) are both indicated for their potential in cardiovascular disease prevention and management, but their combined effects especially in coronary artery disease (CAD) are scarcely examined. This 90-day randomized, double-blind trial aims to investigate the effect of NK and RYR supplementations on cardiometabolic parameters in patients with stable CAD. 178 CAD patients were randomized to four groups: NK + RYR, NK, RYR, and placebo. No adverse effects due to the interventions were reported. In comparisons across groups, NK + RYR showed the maximum effect in reducing triglyceride (-0.39 mmol), total cholesterol (-0.66 mmol/L), diastolic blood pressure (-7.39 mmHg), and increase in high-density lipoprotein cholesterol (0.195 mmol/L) than other groups (all p for multiple groups comparison<0.01). Both NK + RYR and NK groups had significantly better-improved lactate dehydrogenase than the others (-29.1 U/L and - 26.4 U/L). NK + RYR group also showed more potent reductions in thromboxane B2 and increases in antithrombin III compared to placebo (both

Indexed as

anticoagulationcardiometabolic risk factorscoronary artery diseasenattokinasered yeast ricestatin

Identifiers

PMID38812930
PMCPMC11133624

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.